Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Darktrace plc, together with its subsidiaries, engages in the development and sale of cyber-threat defense technology solutions in the United Kingdom, the United States, Canada, Europe, and internationally. Its products include Enterprise Immune System to discover unpredictable cyber-threats; Industrial Immune System to detect novel threats and vulnerabilities, as well as safeguard the integrity and resilience of industrial technologies; and Cyber AI Analyst, an AI investigation technology, which automatically triages, interprets, and reports scope of security incidents. The company also provides Darktrace Antigena, an autonomous response technology for the enterprise with various security products that delivers proactive cyber defense to digital infrastructure. It serves critical national infrastructure organizations, financial services companies, technology and healthcare providers, media corporations, and educational institutions. The company was founded in 2013 and is headquartered in Cambridge, the United Kingdom.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/E
Buy
Sell